Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses

US10000480B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Ryan M. Moslin · Princeton, US
• David S. Weinstein · Plainsboro, US
• Stephen T. Wrobleski · Whitehouse Station, US
• John S. Tokarski · Princeton, US
• Amit Kumar · San Ramon, US
• Douglas G. Batt · Wilmington, US
• Shuqun Lin · Newtown, US
• Chunjian Liu · Pennington, US
• Steven H. Spergel · Warrington, US
• Yanlei Zhang · Princeton, US
• Qingjie Liu · Newtown, US

Key dates

• Filing date: Oct 10, 2016
• Grant date: Jun 19, 2018
• Expiry date: Oct 10, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07B2200/05
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.